Observational Cross-reactivity Study to Evaluate the Specificity of a Blood Test for Colorectal Cancer Diagnosis Based on Molecular Markers and Risk Factors Identified With Artificial Intelligence Tools

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The objective of this observational study is to evaluate the false positive rate of the blood test based on molecular biomarkers and risk factors. A total of 250 patients diagnosed with various cancers and gastrointestinal diseases will be enrolled. The main question to be answered is Does the blood test have a low false positive rate in the main study population? Participants will donate a blood sample as part of their regular medical care for cancer diagnosis and give the consent to know their clinical risk factors.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients older than 18 years of age at the time of blood sample collection.

• Subjects must be able to understand the information provided on the participant information sheet, must consent to participate in the study, and must sign the informed consent form.

• Patients diagnosed with only one type of cancer (no colorectal cacner) or gastrointestinal disease.

Locations
Other Locations
Spain
Hospital Universitario HM Sanchinarro
RECRUITING
Madrid
MD Anderson Cancer Centre
ACTIVE_NOT_RECRUITING
Madrid
Hospitales HM de Malaga
RECRUITING
Málaga
Hospital Universitario de Ourense
RECRUITING
Ourense
Hospital Centro Médico Asturias
RECRUITING
Oviedo
Contact Information
Primary
Marta Jimenez
mjimenez@amadix.com
+34637899149
Time Frame
Start Date: 2023-04-17
Estimated Completion Date: 2025-12
Participants
Target number of participants: 250
Treatments
Cancer or Gastrointestinal Disease
A different types of cancer and gastrointestinal disease will be included in the cohort such as breast cancer, bladder cancer, IBDs, Leukemia and Lung cancer.
Related Therapeutic Areas
Sponsors
Leads: ADVANCED MARKER DISCOVERY S.L.

This content was sourced from clinicaltrials.gov